Pharma Bp

DUBLIN--( BUSINESS WIRE )--The "Emerging Medical Technologies Spotlight" newsletter has been added to ResearchAndMarkets.com's offering. Emerging Medical Technologies (EMT) Spotlight is a resource for strategic marketing, market research, business development, and investment executives seeking discreet and detailed business, market, and competitive intelligence on privately-held companies developing disruptive technologies in 24 markets. This tool currently includes 1855 companies and is updated monthly. LSI leverages multiple data streams to feed this robust resource, including: Private Biotech, Device, and Pharma Companies at Various Stages of Development Company Overviews and/or Executive Summaries from leading industry investment and partnering conferences New companies added regularly outside of the conference circuit via the ongoing efforts of our In-House Research Team The Complete EMT Spotlight Library provides access to all existing companies, new companies added monthly, and company updates through 2012 in all 24 markets. Coverage includes emerging innovations in a broad spectrum of medical technology areas including: Aesthetics/Dermatology Biomaterials Biotechnology/Cell Therapy Cardiovascular Dental Diagnostics Drug Delivery Endocrine Gastroenterology Gynecology/Women's Health Imaging Neurology Oncology Ophthalmology Orthopedics Pain Management Patient Monitoring Pharmaceutical Respiratory Spine Surgery Urology Vascular Wound Company Overviews Data includes: Company Name Technology Details Target Markets Key Executive Contact Info. Location Website Year Established More Executive Summaries Data includes: All Company Overview Data + Development Status Competitive Landscape & Differentiation Financial Summary & Sales Forecasts IP Position & Status Financing Status Investment & Strategic Partnering Needs Management Team Bios More For more information about this newsletter visit https://www.researchandmarkets.com/r/whjnxv

Features Nationally Scaled RNA Sequencing and Specimen Collection for Multiple Sclerosis and Non-Alcoholic Fatty Liver Disease with Plans to Expand NASHVILLE, Tenn., Oct. 18, 2022 /PRNewswire/ -- Decode Health, a healthcare AI company that enables a partner ecosystem to innovate and solve data challenges involving disease risk, today announced a new phase of its collaboration with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, to empower drug and diagnostics research and development in the growing fields of metabolic disease and autoimmune neurology. Continue Reading In earlier phases of the collaboration, the two parties developed RNA (transcriptome) sequencing capabilities based on both parties' next-generation sequencing, analytics and clinical expertise. In this latest phase, the parties have developed a national platform for collecting and storing deidentified consented specimens from individuals participating in research sponsored by pharmaceutical, academic research and patient engagement organizations. The platform includes Quest's 2,100 patient service centers as well as its ExamOne mobile in-home phlebotomy team and a biobank at its advanced laboratory in Memphis, Tenn. Our work will create opportunities to fuel critical advances that unlock cutting-edge diagnostics and therapeutics. Tweet this The collaboration is significant as biomarker-based data can help reduce the time and cost of developing novel diagnostic tests and identifying new drug targets. Nearly 60% of clinical trials include strategies to identify treatment biomarkers.[i] As part of the collaboration, Quest and Decode will share benefits from any research, data licensing, biomarker discovery or diagnostics development that emerge. Additional terms were not disclosed. "RNA analysis holds the potential to ignite the next generation of diagnostics and drug targets for MS and other metabolic and autoimmune neurological disorders," said Jay G. Wohlgemuth, MD, Senior Vice President R&D and Chief Medical Officer, Quest Diagnostics. "To optimize this potential, Quest with Decode Health and other collaborators is mobilizing a nationally scaled sequencing, research and patient engagement platform to empower life science organizations to hasten these discoveries and bring precision medicine to life for patients in the U.S. and globally. At this stage of the collaboration, Decode and Quest's initial focus is on addressing a pressing need for earlier detection, differential diagnosis and therapy selection for multiple sclerosis (MS), which affects about 2.8 million worldwide,[ii]and non-alcoholic fatty liver disease (NAFLD), a metabolic disorder and the most common cause of liver disease worldwide.[iii] Both disorders can be challenging to diagnose, especially at their early stages; MS does not always respond to existing therapies, and NAFLD currently does not have standard therapies available. As the collaboration progresses, the parties plan to expand to additional clinical disease areas. "Opportunities to significantly improve healthcare are hidden within data, especially for diagnostic and drug discoveries," said Chase Spurlock, PhD, Co-founder and CEO of Decode Health. "The work we are doing today with Quest Diagnostics aims to unlock those discoveries. Every day, we are building upon our collective goal to advance precision medicine and improve health outcomes across a growing number of conditions. By collaborating with key healthcare stakeholders, including pharma, we believe that our work will create opportunities to fuel critical advances that unlock the next generation of cutting-edge diagnostics and therapeutics." About Decode Health Decode Health is a healthcare AI company that powers an ecosystem of industry-leading diagnostic and pharmaceutical companies to unlock discoveries with data. Current projects include genomic data creation, RNA diagnostics, and population health analytics. Over the course of a decade, the team leading Decode has built a framework leveraging a variety of advanced machine learning approaches. The company's flexible, scalable approach layers clinical data with SDoH and non-clinical data to fuel innovation and advance precision medicine. Decode's data assets, products, and services improve patient outcomes, lower costs, and promote health equity. For more information, visit . Media Contacts For Decode Health: Nikki Cary [email protected] 615.500.2924 For Quest Diagnostics: Jennifer Petrella [email protected] 973.520.2800 [i] Pharma Precision Medicine Readiness Report 2019 Supplemental Update: Analysis of FDA 2019 Test-Dependent Therapy Approvals - Diaceutics [ii] Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition - PMC (nih.gov) [iii] Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD | Scientific Reports (nature.com) SOURCE Decode Health

Pfizer is investing in new treatments for celiac disease. The Big Pharma shelled out $35 million in equity for Anokion, a Swiss biotech shooting for a celiac therapy. Anokion intends to use the money to fund Phase II studies for the candidate, known as KAN-101 and acquired in a 2019 buyout of Astellas-backed Kanyos Bio. Pfizer also gets a seat each on Anokion’s board of directors and scientific advisory board. “We believe Anokion has a unique opportunity to develop potential durable and disease-modifying treatment options for people with celiac disease and other immune-mediated disorders, and we look forward to supporting them in the continued development of KAN-101,” Michael Vincent, Pfizer’s immunology and inflammation chief, said in a statement. Kanyos Bio originally formed in 2015 out of a partnership between Anokion and Astellas, after which Anokion swallowed the biotech. There are no treatments for celiac disease, and though certain diets can prove effective, trace amounts of gluten can still affect the intestines and cause long-term health consequences. In addition to celiac disease, Anokion is also developing treatments for multiple sclerosis and Type 1 diabetes. The biotech started a Phase I trial for its MS program in January. Verona is continuing to bring in the cash after a positive Phase III trial in August. The biotech announced Monday that it had clinched $150 million in debt financing from Oxford Finance to help provide three years of runway into 2025. Verona took out $10 million immediately and can withdraw another $10 million at its discretion. Another $80 million can be accessed in two parts upon certain milestones, and the final $50 million is subject to Oxford’s approval. The new money comes as Verona plans to submit an NDA for its COPD drug ensifentrine, which passed a Phase III test in August, in the first half of next year. Money from the debt financing can be used toward preparing the NDA and a potential commercial launch, anticipated in 2024 if it’s approved. In Verona’s Phase III ENHANCE-2 study, roughly 800 patients with moderate to severe COPD received ensifentrine or placebo through a nebulizer twice a day for 24 weeks. The study met both its primary and secondary endpoints — different measurements of the FEV1 scale, or how much air patients can exhale in one second.